PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
Ymera Pignochino(Candiolo Cancer Institute), Giovanni Grignani(Candiolo Cancer Institute)
Cited by 70
Related Papers
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
|Molecular Cancer|2009|176